Addex Therapeutics (NASDAQ:ADXN) Stock Price Down 0.5% – Here’s Why

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) shares traded down 0.5% on Monday . The company traded as low as $5.60 and last traded at $5.6690. 1,217 shares were traded during trading, a decline of 58% from the average daily volume of 2,876 shares. The stock had previously closed at $5.70.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Addex Therapeutics in a report on Monday, July 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Addex Therapeutics Price Performance

The stock has a 50 day simple moving average of $6.39 and a two-hundred day simple moving average of $6.88. The company has a market cap of $6.97 million, a price-to-earnings ratio of -0.95 and a beta of 1.50.

About Addex Therapeutics

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.